BiotechTube

Tramadol Hydrochloride 50mg + Celebrex 200mg

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Back Pain

Conditions

Back Pain

Trial Timeline

Mar 1, 2006 → —

NCT ID
NCT00290901

About Tramadol Hydrochloride 50mg + Celebrex 200mg

Tramadol Hydrochloride 50mg + Celebrex 200mg is a approved stage product being developed by Pfizer for Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00290901. Target conditions include Back Pain.

What happened to similar drugs?

8 of 20 similar drugs in Back Pain were approved

Approved (8) Terminated (3) Active (12)
✅tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
✅Diclofenac + CelecoxibPfizerApproved
✅PregabalinPfizerApproved
✅valdecoxib + diclofenacPfizerApproved
✅pregabalin and celecoxib + Placebo and celecoxibPfizerApproved
✅FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%PfizerApproved
✅ThiocolchicosideSanofiApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00290901ApprovedCompleted

Competing Products

20 competing products in Back Pain

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)Johnson & JohnsonPhase 3
40
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
AZD1940 + MidazolamAstraZenecaPhase 1
29